De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Novo Nordisk Beheer

Beheer criteriumcontroles 3/4

De CEO Novo Nordisk's is Lars Jorgensen, benoemd in Jan2017, heeft een ambtstermijn van 7.75 jaar. bezit rechtstreeks 0.002% van de aandelen van het bedrijf, ter waarde DKK 73.94M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 6.6 jaar.

Belangrijke informatie

Lars Jorgensen

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.8yrs
Eigendom CEO	0.002%
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	6.6yrs

Recente managementupdates

Recent updates

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Apr 28

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Apr 14

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Mar 18

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Dec 30

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Dec 12

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Nov 24

Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Aug 20

Analyse CEO-vergoeding

Hoe is Lars Jorgensen's beloning veranderd ten opzichte van Novo Nordisk's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	DKK 90b
Mar 31 2024	n/a	n/a	DKK 89b
Dec 31 2023	n/a	n/a	DKK 84b
Sep 30 2023	n/a	n/a	DKK 75b
Jun 30 2023	n/a	n/a	DKK 67b
Mar 31 2023	n/a	n/a	DKK 61b
Dec 31 2022	DKK 60m	DKK 17m	DKK 56b
Sep 30 2022	n/a	n/a	DKK 53b
Jun 30 2022	n/a	n/a	DKK 51b
Mar 31 2022	n/a	n/a	DKK 49b
Dec 31 2021	DKK 58m	DKK 17m	DKK 48b
Sep 30 2021	n/a	n/a	DKK 46b
Jun 30 2021	n/a	n/a	DKK 44b
Mar 31 2021	n/a	n/a	DKK 43b
Dec 31 2020	DKK 57m	DKK 14m	DKK 42b
Sep 30 2020	n/a	n/a	DKK 42b
Jun 30 2020	n/a	n/a	DKK 41b
Mar 31 2020	n/a	n/a	DKK 40b
Dec 31 2019	DKK 55m	DKK 14m	DKK 39b
Sep 30 2019	n/a	n/a	DKK 39b
Jun 30 2019	n/a	n/a	DKK 38b
Mar 31 2019	n/a	n/a	DKK 38b
Dec 31 2018	DKK 41m	DKK 11m	DKK 39b
Sep 30 2018	n/a	n/a	DKK 38b
Jun 30 2018	n/a	n/a	DKK 39b
Mar 31 2018	n/a	n/a	DKK 39b
Dec 31 2017	DKK 32m	DKK 9m	DKK 38b

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Lars redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Danish markt.

Compensatie versus inkomsten: De vergoeding van Lars is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Lars Jorgensen (58 yo)

7.8yrs

Tenure

DKK 60,100,000

Compensatie

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Lars Jorgensen	President	7.8yrs	DKK 60.10m	0.0021% DKK 74.8m
Karsten Knudsen	Executive VP	6.7yrs	DKK 21.50m	0.000010% DKK 357.8k
Henrik Wulff	Executive VP of Product Supply	no data	DKK 22.00m	0.000060% DKK 2.1m
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	DKK 21.30m	geen gegevens
Martin Lange	Executive VP of Development & Member of the Management Board	3.8yrs	DKK 20.90m	geen gegevens
Marcus Schindler	EVP of Research & Early Development	3.6yrs	DKK 20.90m	geen gegevens
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	geen gegevens	0.0011% DKK 40.4m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	geen gegevens	geen gegevens
Ludovic Helfgott	Executive VP	no data	geen gegevens	geen gegevens
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.6yrs	geen gegevens	geen gegevens
David Moore	Executive VP of Corporate Development & Member of Management Board	1.6yrs	geen gegevens	geen gegevens
Jacob Martin Rode	Head of Investor Relations	no data	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NOVO B wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sylvie Gregoire	Independent Director	9.6yrs	DKK 1.80m	geen gegevens
Helge Lund	Independent Chairman of the Board	7.6yrs	DKK 3.10m	geen gegevens
Henrik Poulsen	Vice Chairman of the Board	3.6yrs	DKK 2.00m	geen gegevens
Laurence Debroux	Independent Director	5.6yrs	DKK 2.00m	geen gegevens
Martin MacKay	Independent Director	6.6yrs	DKK 1.70m	geen gegevens
Andreas Fibig	Independent Director	6.6yrs	DKK 1.40m	geen gegevens
Kasim Kutay	Non-Independent Director	7.6yrs	DKK 1.20m	geen gegevens
Christina Law	Independent Director	2.6yrs	DKK 1.30m	geen gegevens
Liselotte Hyveled	Employee Representative Director	2.6yrs	DKK 800.00k	0% DKK 0
Mette Jensen	Employee Non-Independent Representative Director	6.6yrs	DKK 1.20m	geen gegevens
Thomas Rantzau	Employee Representative Non-Independent Director	6.8yrs	DKK 1.00m	geen gegevens
Elisabeth Christensen	Employee Representative Director	2.6yrs	DKK 800.00k	geen gegevens

6.6yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NOVO B wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.6 jaar).

Novo Nordisk Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Employee Representative Director recently sold kr.7.6m worth of stock

Key Executive recently sold kr.50m worth of stock

President recently sold kr.145m worth of stock

Insider recently sold kr.10m worth of stock

Recent updates

Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Now 20% undervalued after recent price drop

Employee Representative Director recently sold kr.7.6m worth of stock

Now 20% undervalued after recent price drop

Second quarter 2024 earnings: EPS misses analyst expectations

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Key Executive recently sold kr.50m worth of stock

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Final dividend of kr.6.40 announced

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Price target increased by 14% to kr.887

President recently sold kr.145m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Insider recently sold kr.10m worth of stock

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Price target increased by 7.6% to kr.672

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd